FDA User Fees 2012: Hearing on Issues Related to Accelerated Approval, Medical Gas, Antibiotic Development and Downstream Pharmaceutical Supply Chain

Panel I

Janet Woodcock, MD

• Director
• Center for Drug Evaluation and Research
• U.S. Food and Drug Administration
• Witness Testimony

Panel II

John Maraganore, PhD.

• Chief Executive Officer
• Alnylam Pharmaceuticals 
• Witness Testimony (Truth in Testimony)

Jeff Allen, PhD.

• Executive Director
• Friends of Cancer Research
• Witness Testimony (Truth in Testimony)

Barry Eisenstein, M.D., FACP, FIDSA, FAAM

• Senior Vice President
• Scientific Affairs
• Cubist Pharmaceuticals
• Witness Testimony (Truth in Testimony)

John H. Powers, MD, FACP, FIDSA

• Assistant Clinical Professor of Medicine
• George Washington University School of Medicine
• Witness Testimony

Michael D. Walsh

• President
• LifeGas on behalf of Compress Gas Association
• Witness Testimony 

Panel III

Shawn Brown

• Vice President
• State Government Affairs
• Generic Pharmaceutical Association
• Witness Testimony (Supporting Document) (Truth in Testimony)

Elizabeth A. Gallenagh, JD

• Vice President
• Government Affairs
• General Counsel
• Healthcare Distribution Management Association
• Witness Testimony (Truth in Testimony)

Tim Davis, Pharm.D.

• Beaver Health Mart Pharmacy on behalf of National Community Pharmacists Association
• Witness Testimony (Supporting Document)

Allan Coukell

• Director
• Medical Programs
• Pew Health Group, The Pew Charitable Trusts
• Witness Testimony (Supporting Document) (Truth in Testimony)